

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

**SANGAMO BIOSCIENCES ANNOUNCES PRESENTATION AT THE WALL
STREET ANALYST FORUM**

Richmond, CA – November 11, 2002 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that Edward Lanphier, the company's president and chief executive officer, will present at The Wall Street Analyst Forum's Institutional Investor Conference in New York on Tuesday, November 12th at 12:30 pm Eastern Time. The audio presentation will be webcast live and a replay of the presentation will be available for 15 days after the conference; both can be accessed via the following link http://media.corporate-ir.net/media_files/Event/2002/nov/wsaf/111102.htm.

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of coronary artery disease and peripheral arterial disease. Other therapeutic development programs are focused on cancer, ophthalmic and infectious diseases. Sangamo's proprietary technology enables the engineering of transcription factors known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP TF technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

Contact: Elizabeth Wolffe, Ph.D.
510-970-6000, x271
ewolffe@sangamo.com

###